Comparative Effects of a D2 and Mixed D1-D2 Dopamine Antagonist on Gambling and Amphetamine Reinforcement in Pathological Gamblers and Healthy ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2009-2015

ABSTRACT

To determine if: 1. pathological gambling is similar to psychostimulant addiction as reflected by parallel roles for D1 and D2 receptors in gambling and stimulant reinforcement. 2. these parallel roles are linked with gambling pathology or if they are evident in both gamblers and controls. Detailed Description BACKGROUND: No previous research appears to have investigated the role of dopamine (DA) D1 or D2 receptors in psychostimulant reinforcement in pathological gamblers. Effects of haloperidol vs. placebo will reveal the role of D2 and the effects of fluphenazine vs. haloperidol will reveal the role of D1 in this process. OBJECTIVE: This study will begin to define the neurochemistry of Pathological Gambling by examining the roles of dopamine D1 and D2 receptors in gambling reinforcement and psychostimulant reinforcement, and exploring genetic predictors of response to DA probes in Pathological Gambling subjects (subjects) and healthy controls. METHODS: A double-blind, placebo controlled, counterbalanced between-within design will be employed. Each participant will attend 4 sessions with a minimum of 1 week between sessions to ensure drug washout. Responses to the slot machine will be assessed in sessions 1 and 2 (Phase I), and responses to amphetamine will be assessed in sessions 3 and 4 (Phase II). A second capsule (dummy) will be administered at expected peak levels for each antagonist on sessions 1 and 2 to standardize the procedure across sessions. Subjective reinforcement self-report scales will be administered at key intervals throughout the study. HYPOTHESIS: It is hypothesized that haloperidol (3-mg) will increase priming (Desire to Gamble, Gambling word salience) and pleasurable effects (e.g., Enjoyment/Liking) induced by playing a slot machine in Pathological Gambling subjects (N = 40). If gambling and stimulant reinforcement are mediated by common mechanisms, haloperidol will also increase priming and pleasurable effects of amphetamine (20-mg) in Pathological Gambling subjects. If D1 mediates effects of haloperidol, the mixed D1-D2 antagonist, fluphenazine (fluphenazine; 3-mg) will decrease or not alter responses to the slot machine and amphetamine in Pathological Gambling subjects. If D2 deficits are linked with gambling pathology, haloperidol will not affect slot machine or amphetamine reinforcement in controls (N= 40). If D1 deficits are linked with gambling pathology, fluphenazine will increase gambling and amphetamine reinforcement in controls, by mitigating undue D1 activation in subjects with high baseline D1 function. If D1 or D2 genes contribute to gambling or amphetamine reinforcement, genotype will predict responses to the manipulations. More... »

URL

https://clinicaltrials.gov/show/NCT02203786

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3468", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "To determine if: 1. pathological gambling is similar to psychostimulant addiction as reflected by parallel roles for D1 and D2 receptors in gambling and stimulant reinforcement. 2. these parallel roles are linked with gambling pathology or if they are evident in both gamblers and controls.\n\nDetailed Description\nBACKGROUND: No previous research appears to have investigated the role of dopamine (DA) D1 or D2 receptors in psychostimulant reinforcement in pathological gamblers. Effects of haloperidol vs. placebo will reveal the role of D2 and the effects of fluphenazine vs. haloperidol will reveal the role of D1 in this process. OBJECTIVE: This study will begin to define the neurochemistry of Pathological Gambling by examining the roles of dopamine D1 and D2 receptors in gambling reinforcement and psychostimulant reinforcement, and exploring genetic predictors of response to DA probes in Pathological Gambling subjects (subjects) and healthy controls. METHODS: A double-blind, placebo controlled, counterbalanced between-within design will be employed. Each participant will attend 4 sessions with a minimum of 1 week between sessions to ensure drug washout. Responses to the slot machine will be assessed in sessions 1 and 2 (Phase I), and responses to amphetamine will be assessed in sessions 3 and 4 (Phase II). A second capsule (dummy) will be administered at expected peak levels for each antagonist on sessions 1 and 2 to standardize the procedure across sessions. Subjective reinforcement self-report scales will be administered at key intervals throughout the study. HYPOTHESIS: It is hypothesized that haloperidol (3-mg) will increase priming (Desire to Gamble, Gambling word salience) and pleasurable effects (e.g., Enjoyment/Liking) induced by playing a slot machine in Pathological Gambling subjects (N = 40). If gambling and stimulant reinforcement are mediated by common mechanisms, haloperidol will also increase priming and pleasurable effects of amphetamine (20-mg) in Pathological Gambling subjects. If D1 mediates effects of haloperidol, the mixed D1-D2 antagonist, fluphenazine (fluphenazine; 3-mg) will decrease or not alter responses to the slot machine and amphetamine in Pathological Gambling subjects. If D2 deficits are linked with gambling pathology, haloperidol will not affect slot machine or amphetamine reinforcement in controls (N= 40). If D1 deficits are linked with gambling pathology, fluphenazine will increase gambling and amphetamine reinforcement in controls, by mitigating undue D1 activation in subjects with high baseline D1 function. If D1 or D2 genes contribute to gambling or amphetamine reinforcement, genotype will predict responses to the manipulations.", 
    "endDate": "2015-09-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02203786", 
    "keywords": [
      "comparative effect", 
      "dopamine antagonist", 
      "gambling", 
      "reinforcement", 
      "pathological gambler", 
      "psychostimulant addiction", 
      "parallel", 
      "D1 and D2", 
      "receptor", 
      "pathology", 
      "gambler", 
      "control", 
      "previous research", 
      "DA", 
      "D1 or D2", 
      "psychostimulants", 
      "haloperidol", 
      "placebo", 
      "D2", 
      "fluphenazine", 
      "D1", 
      "neurochemistry", 
      "dopamine", 
      "genetic predictor", 
      "probe", 
      "healthy control", 
      "method", 
      "session", 
      "washout", 
      "machine", 
      "Session 1", 
      "amphetamine", 
      "session 3", 
      "Phase II", 
      "capsule", 
      "dummy", 
      "peak level", 
      "antagonist", 
      "self-report scale", 
      "key interval", 
      "priming", 
      "desire", 
      "gamble", 
      "common mechanism", 
      "decrease", 
      "deficit", 
      "baseline", 
      "gene", 
      "genotype", 
      "manipulation"
    ], 
    "name": "Comparative Effects of a D2 and Mixed D1-D2 Dopamine Antagonist on Gambling and Amphetamine Reinforcement in Pathological Gamblers and Healthy Controls", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02203786"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00017.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.248883.d", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.155956.b", 
        "type": "Organization"
      }
    ], 
    "startDate": "2009-09-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1002/j.1552-4604.1998.tb04395.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005584040"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00542363", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017585623", 
          "https://doi.org/10.1007/bf00542363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0376-8716(02)00104-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029664050"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1530-0277.2001.tb02146.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038527170"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1038/clpt.1983.65", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042912921"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1176/ajp.144.9.1184", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063477712"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02203786"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02203786'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02203786'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02203786'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02203786'


 

This table displays all metadata directly associated to this object as RDF triples.

90 TRIPLES      16 PREDICATES      72 URIs      59 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02203786 schema:about anzsrc-for:3468
2 schema:description To determine if: 1. pathological gambling is similar to psychostimulant addiction as reflected by parallel roles for D1 and D2 receptors in gambling and stimulant reinforcement. 2. these parallel roles are linked with gambling pathology or if they are evident in both gamblers and controls. Detailed Description BACKGROUND: No previous research appears to have investigated the role of dopamine (DA) D1 or D2 receptors in psychostimulant reinforcement in pathological gamblers. Effects of haloperidol vs. placebo will reveal the role of D2 and the effects of fluphenazine vs. haloperidol will reveal the role of D1 in this process. OBJECTIVE: This study will begin to define the neurochemistry of Pathological Gambling by examining the roles of dopamine D1 and D2 receptors in gambling reinforcement and psychostimulant reinforcement, and exploring genetic predictors of response to DA probes in Pathological Gambling subjects (subjects) and healthy controls. METHODS: A double-blind, placebo controlled, counterbalanced between-within design will be employed. Each participant will attend 4 sessions with a minimum of 1 week between sessions to ensure drug washout. Responses to the slot machine will be assessed in sessions 1 and 2 (Phase I), and responses to amphetamine will be assessed in sessions 3 and 4 (Phase II). A second capsule (dummy) will be administered at expected peak levels for each antagonist on sessions 1 and 2 to standardize the procedure across sessions. Subjective reinforcement self-report scales will be administered at key intervals throughout the study. HYPOTHESIS: It is hypothesized that haloperidol (3-mg) will increase priming (Desire to Gamble, Gambling word salience) and pleasurable effects (e.g., Enjoyment/Liking) induced by playing a slot machine in Pathological Gambling subjects (N = 40). If gambling and stimulant reinforcement are mediated by common mechanisms, haloperidol will also increase priming and pleasurable effects of amphetamine (20-mg) in Pathological Gambling subjects. If D1 mediates effects of haloperidol, the mixed D1-D2 antagonist, fluphenazine (fluphenazine; 3-mg) will decrease or not alter responses to the slot machine and amphetamine in Pathological Gambling subjects. If D2 deficits are linked with gambling pathology, haloperidol will not affect slot machine or amphetamine reinforcement in controls (N= 40). If D1 deficits are linked with gambling pathology, fluphenazine will increase gambling and amphetamine reinforcement in controls, by mitigating undue D1 activation in subjects with high baseline D1 function. If D1 or D2 genes contribute to gambling or amphetamine reinforcement, genotype will predict responses to the manipulations.
3 schema:endDate 2015-09-01T00:00:00Z
4 schema:keywords D1
5 D1 and D2
6 D1 or D2
7 D2
8 DA
9 Phase II
10 Session 1
11 amphetamine
12 antagonist
13 baseline
14 capsule
15 common mechanism
16 comparative effect
17 control
18 decrease
19 deficit
20 desire
21 dopamine
22 dopamine antagonist
23 dummy
24 fluphenazine
25 gamble
26 gambler
27 gambling
28 gene
29 genetic predictor
30 genotype
31 haloperidol
32 healthy control
33 key interval
34 machine
35 manipulation
36 method
37 neurochemistry
38 parallel
39 pathological gambler
40 pathology
41 peak level
42 placebo
43 previous research
44 priming
45 probe
46 psychostimulant addiction
47 psychostimulants
48 receptor
49 reinforcement
50 self-report scale
51 session
52 session 3
53 washout
54 schema:name Comparative Effects of a D2 and Mixed D1-D2 Dopamine Antagonist on Gambling and Amphetamine Reinforcement in Pathological Gamblers and Healthy Controls
55 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02203786
56 schema:sdDatePublished 2019-03-07T15:25
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher Nde305b65c90b4794a5fffab0da5b30f6
59 schema:sponsor https://www.grid.ac/institutes/grid.155956.b
60 https://www.grid.ac/institutes/grid.248883.d
61 schema:startDate 2009-09-01T00:00:00Z
62 schema:subjectOf sg:pub.10.1007/bf00542363
63 https://doi.org/10.1002/j.1552-4604.1998.tb04395.x
64 https://doi.org/10.1016/s0376-8716(02)00104-7
65 https://doi.org/10.1038/clpt.1983.65
66 https://doi.org/10.1111/j.1530-0277.2001.tb02146.x
67 https://doi.org/10.1176/ajp.144.9.1184
68 schema:url https://clinicaltrials.gov/show/NCT02203786
69 sgo:license sg:explorer/license/
70 sgo:sdDataset clinical_trials
71 rdf:type schema:MedicalStudy
72 Nde305b65c90b4794a5fffab0da5b30f6 schema:name Springer Nature - SN SciGraph project
73 rdf:type schema:Organization
74 anzsrc-for:3468 schema:inDefinedTermSet anzsrc-for:
75 rdf:type schema:DefinedTerm
76 sg:pub.10.1007/bf00542363 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017585623
77 https://doi.org/10.1007/bf00542363
78 rdf:type schema:CreativeWork
79 https://doi.org/10.1002/j.1552-4604.1998.tb04395.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1005584040
80 rdf:type schema:CreativeWork
81 https://doi.org/10.1016/s0376-8716(02)00104-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029664050
82 rdf:type schema:CreativeWork
83 https://doi.org/10.1038/clpt.1983.65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042912921
84 rdf:type schema:CreativeWork
85 https://doi.org/10.1111/j.1530-0277.2001.tb02146.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1038527170
86 rdf:type schema:CreativeWork
87 https://doi.org/10.1176/ajp.144.9.1184 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063477712
88 rdf:type schema:CreativeWork
89 https://www.grid.ac/institutes/grid.155956.b schema:Organization
90 https://www.grid.ac/institutes/grid.248883.d schema:Organization
 




Preview window. Press ESC to close (or click here)


...